Ausgabe 2/2017
Special Issue: Angiogenesis Inhibitors in Combinatorial Approaches
Inhalt (8 Artikel)
Angiogenesis inhibitors in combinatorial approaches
Patrycja Nowak-Sliwinska, Arjan W. Griffioen
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan, Arjan W. Griffioen, Dan G. Duda
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
Teele Kuusk, Laurence Albiges, Bernard Escudier, Nikolaos Grivas, John Haanen, Thomas Powles, Axel Bex
The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future
Lisanne C. Hamming, Ben J. Slotman, Henk M. W. Verheul, Victor L. Thijssen
Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists
MariaRosa Bani, Alessandra Decio, Raffaella Giavazzi, Carmen Ghilardi
Erratum to: Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists
MariaRosa Bani, Alessandra Decio, Raffaella Giavazzi, Carmen Ghilardi
Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment
Robert H. Berndsen, U. Kulsoom Abdul, Andrea Weiss, Marloes Zoetemelk, Marije T. te Winkel, Paul J. Dyson, Arjan W. Griffioen, Patrycja Nowak-Sliwinska
miRNAs: micro-managers of anticancer combination therapies
Judy R. van Beijnum, Elisa Giovannetti, Dennis Poel, Patrycja Nowak-Sliwinska, Arjan W. Griffioen